Reward Anticipation Is Differentially Modulated by Varenicline and Nicotine in Smokers

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
John R FedotaE A Stein

Abstract

Recidivism rates for cigarette smokers following treatment often exceed 80%. Varenicline is the most efficacious pharmacotherapy currently available with cessation rates of 25-35% following a year of treatment. Although the in vivo binding properties are well known, varenicline's neurobiological mechanisms of action are still poorly understood. Varenicline acts as a nicotinic receptor partial agonist or antagonist depending on the presence or absence of nicotine and has been implicated in the reduction of reward signaling more broadly. The current study probed anticipatory reward processing using a revised monetary incentive delay task during fMRI in cohorts of smokers and non-smokers who completed a two-drug, placebo-controlled, double-blind crossover study. All participants underwent ~17 days of order-balanced varenicline and placebo pill administration and were scanned under each condition wearing a transdermal nicotine or placebo patch. Consistent with nicotine's ability to enhance the rewarding properties of nondrug stimuli, acute nicotine administration enhanced activation in response to reward-predicting monetary cues in both smokers and non-smokers. In contrast, varenicline reduced gain magnitude processing, but did so ...Continue Reading

References

Jun 1, 1996·Computers and Biomedical Research, an International Journal·R W Cox
Dec 22, 1998·Brain Research. Brain Research Reviews·K C Berridge, T E Robinson
Mar 7, 2002·Neuron·John P O'DohertyRaymond J Dolan
Oct 3, 2002·The American Journal of Psychiatry·Rita Z Goldstein, Nora D Volkow
Dec 10, 2002·Archives of General Psychiatry·Arthur L BrodyMurray E Jarvik
Oct 16, 2004·Science·K Richard RidderinkhofSander Nieuwenhuis
May 13, 2005·Journal of Medicinal Chemistry·Jotham W CoeBrian T O'Neill
Oct 28, 2005·Nature Neuroscience·Barry J Everitt, Trevor W Robbins
Jun 17, 2006·Annual Review of Neuroscience·Steven E HymanEric J Nestler
Sep 15, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Juliana YacubianChristian Büchel
Nov 15, 2006·Journal of Clinical Pharmacology·Hélène M FaesselAaron H Burstein
Jul 13, 2007·Proceedings of the National Academy of Sciences of the United States of America·Pia SteenslandSelena E Bartlett
Jan 15, 2008·Cognitive, Affective & Behavioral Neuroscience·Cameron S Carter, Vincent van Veen
Jul 26, 2008·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·George F Koob, Michel Le Moal
Oct 10, 2008·Biological Psychiatry·Freda PattersonCaryn Lerman
Mar 3, 2009·Biological Psychiatry·Sherry A McKeeErika Balchunas
Apr 28, 2009·Nature Neuroscience·Nikolaus KriegeskorteChris I Baker
Aug 28, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·George F Koob, Nora D Volkow
Dec 26, 2009·Social Cognitive and Affective Neuroscience·Matthew D Lieberman, William A Cunningham
Jul 30, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Linzy M HendricksonAndrew R Tapper
Jan 5, 2011·Archives of General Psychiatry·Teresa FranklinAnna Rose Childress
Jan 12, 2011·Psychopharmacology·Lisa M FucitoStephanie S O'Malley
Mar 29, 2011·Annual Review of Neuroscience·Mariella De Biasi, John A Dani
Apr 20, 2011·Proceedings of the National Academy of Sciences of the United States of America·Richard ExleyPhilippe Faure
May 12, 2011·Psychopharmacology·Thomas H BrandonBrent J Small
Oct 21, 2011·Nature Reviews. Neuroscience·Rita Z Goldstein, Nora D Volkow
Jan 28, 2012·Cognitive, Affective & Behavioral Neuroscience·Tara A NiendamCameron S Carter
Apr 14, 2012·Current Biology : CB·Clayton Hickey, Wieske van Zoest
Feb 5, 2013·NeuroImage·Gang ChenRobert W Cox
Feb 12, 2013·Current Opinion in Neurobiology·Xavier NoëlAntoine Bechara
Aug 8, 2013·CNS Spectrums·Robert Hester, Maartje Luijten
Oct 17, 2013·Experimental and Clinical Psychopharmacology·Brian A AndersonCherie L Marvel
Sep 11, 2014·JAMA Psychiatry·Michele L PergadiaDiego A Pizzagalli

❮ Previous
Next ❯

Citations

May 5, 2016·Drug and Alcohol Dependence·Jeffrey M EngelmannPaul M Cinciripini
Aug 23, 2016·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Emma Jane RoseElliot A Stein
Oct 24, 2017·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Lauren V MoranA Eden Evins
Sep 22, 2016·Journal of Psychopharmacology·Amanda Bischoff-GretheUNKNOWN TMARC Group
Mar 28, 2018·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Merideth A AddicottF Joseph McClernon
Jan 30, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·E LesageE A Stein
May 19, 2019·Journal of Community Psychology·Brittney Keller-HamiltonAmy K Ferketich
Feb 13, 2017·Psychopharmacology·Merideth A AddicottF Joseph McClernon
May 9, 2021·Annual Review of Clinical Psychology·Timothy B Baker, Danielle E McCarthy

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.